MELA Sciences Announces the Results of its Third Clinical Advisory Meeting and the Four Clinical Posters Presented at the Winter

  MELA Sciences Announces the Results of its Third Clinical Advisory Meeting
  and the Four Clinical Posters Presented at the Winter Clinical Dermatology

Business Wire

IRVINGTON, N.Y. -- January 22, 2014

MELA Sciences, Inc. (NASDAQ: MELA), developer of MelaFind^®, an FDA approved
optical diagnostic device that assists dermatologists in the diagnosis of
melanoma, today announced the results of its third company-sponsored Clinical
Advisory meeting hosted during the Winter Clinical Dermatology Conference in
Hawaii where technical advancements of MelaFind^® and future technology
development opportunities were discussed and user’s validated its clinical
use. MELA Sciences also displayed four clinical posters presentations at the
conference, which took place from January 17 – 22, 2014.

The poster presentations reviewed clinical data derived from practice and
clinical settings that highlighted how MelaFind has helped dermatologists in
the assessment of clinically ambiguous pigmented skin lesions in various
patients including young adults, an area of growing concern, and those with
atypical mole syndrome. To view the posters and their accompanying abstract
please click here.

The poster authored by Dr. Darrell Rigel, titled Physical Properties, Novel
Features and Clinical Validation of a Multispectral Digital Skin Lesion
Analysis Device for Melanoma, and outlined below was named Poster of the Day
on the first day of the conference.

Highlights of the studies and the data shown in the poster presentations are
as follows:

Physical Properties, Novel Features and Clinical Validation of a Multispectral
Digital Skin Lesion Analysis Device (MSDSLA) for Melanoma Detection - Darrell
S. Rigel, MD, MS NYU School of Medicine, New York, NY; Laura Ferris, MD, PhD,
University of Pittsburgh. Pittsburgh, PA; Arthur Sober, MD, Harvard
University, Boston, MA; Clay J. Cockerell, MD, University of Texas
Southwestern, Dallas, TX

  *Retrospective data from the MelaFind pivotal study was used to investigate
    the MelaFind multispectral images and classifier score result as a tool to
    differentiate cutaneous melanoma from other pigments skin lesions.
  *Results showed the average classifier scores of melanomas, high-grade
    lesions, non-melanoma skin cancers, and histologically benign nevi were
    3.5, 2.7, 2.6 and 1.6 respectively.
  *Further results showed an increase in the mean classifier score result
    with each additional clinical characteristic present in the lesion.

Assessing the Predictive Probability of Melanoma and Other High Risk Pigmented
Lesions Using Data Provided by a Multispectral digital Skin Lesion Analysis
Device - Jane Yoo, MD, MPP, Dept. of Dermatology, Albert Einstein School of
Medicine, Bronx, NY; Natalie Tucker, BS, MELA Sciences, Irvington, NY; Darrell
S. Rigel, MD, MS, Dept. of Dermatology, NYU School of Medicine, NYC, NY

  *A risk prediction model was built to assess the predictive probability of
    melanoma or a high-risk lesion for consideration for biopsy based on data
    obtained from MelaFind.
  *Results show a potential quantitative predictive capacity for presence of
    melanoma and other high risk pigmented lesions using the MelaFind device.

In addition to presenting data from the four studies, MELA Sciences held its
third Clinical Advisory Meeting for current and prospective MelaFind users and
thought leaders. In attendance was Dr. Antonanella Calame, dermatologist,
dermatopathologist and medical director of Compass Dermatology and
Dermatopathology in La Jolla, CA. Dr. Calame, a user of MelaFind, said, “As
dermatologists, one of our most important goals is diagnosing melanoma, the
deadliest form of skin cancer, at its earliest and most curable stage. The
MelaFind system’s images and data analysis tools help dermatologists with one
of the most challenging questions we face each day when evaluating clinically
ambiguous pigments skin lesions: “Is this lesion atypical enough for me to
remove and investigate further via histology?” MelaFind’s analysis of a
lesion’s architectural structure gives us access to new information deeper
into the skin, where the human eye cannot see, and helps us answer this
critical question, improving overall outcomes for both patient and clinician.
These tools are available for the first time in medicine and MelaFind is just
the beginning. If patient outcomes are our foremost concern, adoption of such
technologies should be widespread and soon become part of the standard of

The Winter Clinical Dermatology Conference was conducted over four days and
had nearly 400 participants from various fields of dermatology, medical and
cosmetic. In discussing the Advances in the Diagnosis of Melanoma, Dr. Laura
Ferris credited MelaFind as an important instrument in helping to detect

Please follow us:                 
                   Twitter:            @MELASciencesIR or @MelaFind
                   StockTwits:         @MELASciencesIR

About MELA Sciences, Inc.

MELA Sciences is a medical device company developing dermatology diagnostics
utilizing state-of-the-art optical imaging. The flagship product is
MelaFind^®, an FDA, PMA and CE Mark approved, non-invasive diagnostic tool to
aid dermatologists in melanoma evaluation and diagnosis. MelaFind^® uses a
variety of visible to near-infrared light waves to evaluate skin lesions from
the surface to 2.5 mm beneath the skin. It provides images and data on the
relative disorganization of a lesion's structure that provides substantial
additional perspective to aid melanoma diagnosis. MELA is also exploring new
potential uses for its core imaging technology and algorithms.

Safe Harbor

This press release includes "forward-looking statements" within the meaning of
the Securities Litigation Reform Act of 1995. These statements include but are
not limited to our plans, objectives, expectations and intentions and may
contain words such as “seeks,” “look forward,” and “there seems” that suggest
future events or trends. These statements are based on our current
expectations and are inherently subject to significant uncertainties and
changes in circumstances. Actual results may differ materially from our
expectations due to financial, economic, business, competitive, market,
regulatory and political factors or conditions affecting the company and the
medical device industry in general, as well as more specific risks and
uncertainties set forth in the company’s SEC reports on Forms 10-Q and 10-K.
Given such uncertainties, any or all of these forward-looking statements may
prove to be incorrect or unreliable. MELA Sciences assumes no duty to update
its forward-looking statements and urges investors to carefully review its SEC
disclosures available at and


MELA Sciences, Inc.
Diana Garcia Redruello, 212-518-4226
Catalyst Global
Toni Trigiani or David Collins, 212-924-9800
Press spacebar to pause and continue. Press esc to stop.